During this year’s first quarter, used EV sales in the U.S. jumped 12 percent, year on year, and 17 percent compared to the previous three months, the Financial Times reported.
Category: 14 April 2026
Post
GOING OUT OF BUSINESS TRENDS
This week brought fresh signs of economic strain as an increasing number of businesses – from small local operators to well-known brands –announced closures, restructurings, or bankruptcy filings.
Post
INVESTORS FLEE JUNK BONDS
During the 30 days ending 6 April, investors yanked an average of $2.7 billion a week out of the junk bond market, fleeing to defensive positions as the Iran War’s economic fallout makes risky holdings even more so.
Post
SALES OF EXISTING HOMES DROP TO NINE-MONTH LOW
In March, U.S. sales of existing homes fell 3.6 percent, year over year, to 3.98 million, the slowest pace since June 2025, the National Association of Realtors (NAR) reported.
Post
CONSUMER SENTIMENT DROPS TO RECORD LOW IN NEW SURVEY
American consumers’ view of the country’s economy is worse than it has ever been, according to the University of Michigan’s latest monthly survey.
Post
UNEMPLOYMENT CLAIMS JUMP IN BEGINNING OF APRIL
In the week ending 4 April, new claims for jobless benefits rose 16,000 from the previous week to reach 219,000, the highest level since the week ending 7 February.
Post
HOME FORECLOSURE PRESSURES INCREASE IN THE K-SHAPED ECONOMY
In this year’s first quarter, legal requests related to home foreclosures leaped up 20.3 percent from a year earlier, according to LegalShield’s Consumer Stress Legal Index.
Post
IN MARCH, U.S. CONSUMER PRICES ROSE MOST IN FOUR YEARS
In March, the U.S. Consumer Price Index (CPI) shot up 0.9 percent above February’s level, the largest monthly jump since 2022 as the Iran War hiked gasoline prices by 35 percent or more.
Post
GAZA/LEBANON DEATH TOLLS
The IDF has killed at least 72,336 Palestinians in Gaza, and an additional 172,213 have been wounded as Israel continues to carry out strikes and attacks on the enclave, despite the so-called ceasefire announced in October 2025.
Post
SPOTLIGHT: BIGS GETTING BIGGER
Gilead Sciences, a California pharma, is paying $3.15 billion to take over Tubulis, a German developer of drugs that more effectively deliver chemotherapy treatments to cancer tumors.